organization

ApoPharma

APO-PHARMA INC CORP
  • project . 2011 - 2015
    Funder: EC Project Code: 277984
    Open Access mandate for Publications Special Clause 39
    Partners: OHSU, BAYFOR, LMU MUENCHEN, KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN, ACIES BIO, FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Newcastle University, ApoPharma, HOFFNUNGSBAUM EV VEREIN ZUR FORDERUNG DER ERFORSCHUNG UND BEHANDLUNG VON NBIA (VORMALS: HALLERVORDEN-SPATZ-SYNDROM)*TREE OF HOPE EV, CZD...
  • project . 2011 - 2016
    Funder: EC Project Code: 261483
    Open Access mandate for Publications Special Clause 39
    Partners: APOTEX INC CORPORATION, CNGMO, Leiden University, QSUT UHCT, Ospedale Vincenzo Cervello, Ministry of Health of the Republic of Cyprus, FONDAZIONE GIANNI BENZI ONLUS, AOU, ApoPharma, UCL...
  • project . 2015 - 2021
    Funder: EC Project Code: 633190
    Overall Budget: 8,263,200 EURFunder Contribution: 5,998,990 EUR
    Open Access mandate for Publications
    Partners: PRES, University of Tübingen, UPMC, University of Ulm, CAU, Centre Hospitalier Régional et Universitaire de Lille, UNIVERSITÄTSKLINIKUM SCHLESWIG-HOLSTEIN, INSERM, Inserm Transfert, Newcastle University...

    Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxida...

Any information missing or wrong?Report an Issue